SCHEMBL4070692

SCHEMBL4070692

CN(C(=O)c1ccc(Cl)nc1)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.51
KCNQ2 O43526 1/20 0.51
KCNE1 P15382 1/20 0.51
KCNQ1 P51787 1/20 0.51
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
EGFR P00533 2/20 0.47
TRPV4 Q9HBA0 1/20 0.47
GRM5 P41594 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
RAB9A P51151 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.44
POLB P06746 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799575 0.88 KCNQ3 (0.55) KCNQ3KCNQ2KCNE1KCNQ1KMT2A
SCHEMBL4067469 0.88 KMT2A (0.55) KCNQ3KCNQ2KMT2AMEN1ALDH1A1
SCHEMBL333999 0.80 NAPRT (0.60) KCNQ3KCNQ2KCNE1KCNQ1KMT2A
SCHEMBL31606802 0.80 NAPRT (0.60) KCNQ3KCNQ2KCNE1KCNQ1KMT2A
SCHEMBL790737 0.80 TRPV1 (0.55) KMT2AMEN1ALDH1A1LMNANAPRT
SCHEMBL23367841 0.77 SMN1; SMN2 (0.60) ALDH1A1LMNAEGFRSMN1; SMN2RAB9A
SCHEMBL97673 0.76 EGFR (0.48) KMT2AMEN1ALDH1A1LMNAEGFR
SCHEMBL7410067 0.76 CHEK2 (0.49) KMT2AMEN1ALDH1A1LMNAEGFR
SCHEMBL7400709 0.76 EGFR (0.48) KMT2AMEN1ALDH1A1LMNAEGFR
SCHEMBL12311615 0.75 KMT2A (0.64) KMT2AMEN1ALDH1A1LMNAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028945-B9 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2009-02-18 EP disclosed
EP-1028945-B1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2007-07-11 EP disclosed
US-6458813-B1 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER AMGEN INC. 2002-10-01 US disclosed
US-20020035094-A1 Substituted pyridine compounds and methods of use AMGEN INC. 2002-03-21 US disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 US disclosed
US-6184237-B1 Substituted pyridine compounds and methods of use AMGEN INC. 2001-02-06 US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
US-6022884-A PROPHYLAXIS OR TREATMENT OF INFLAMMATION AMGEN INC. (US) 2000-02-08 US disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035094-A1 Substituted pyridine compounds and methods of use IL1B, IL6, IL1A KCNQ3 2395/4885KCNQ2 2157/4885KCNE1 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.